SCHEMBL14582014

SCHEMBL14582014

Cc1ccccc1N=Nc1ccc(NC(=O)c2cccs2)c(C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.59
GPR174 Q9BXC1 1/20 0.58
APEX1 P27695 1/20 0.51
MAPT P10636 6/20 0.50
KMT2A Q03164 5/20 0.50
ALDH1A1 P00352 4/20 0.50
MEN1 O00255 4/20 0.50
KDM4E B2RXH2 3/20 0.50
LMNA P02545 3/20 0.50
PKM P14618 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 2/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 2/20 0.48
USP2 O75604 1/20 0.48
TP53 P04637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14130007 0.83 AHR (0.66) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL14130404 0.83 AHR (0.66) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL14130403 0.81 AHR (0.64) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL23259385 0.80 KMT2A (0.64) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL26104727 0.80 KMT2A (0.64) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL14612980 0.80 AHR (0.62) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL7991476 0.78 MAPT (0.68) GPR174MAPTKMT2AALDH1A1MEN1
SCHEMBL20762595 0.78 AHR (0.66) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL14582010 0.78 AHR (0.60) AHRMAPTKMT2AALDH1A1MEN1
SCHEMBL29506632 0.77 AHR (0.62) AHRMAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032458-A1 Compound having activity for inhibiting dioxin toxicity, pharmaceutical composition comprising the compound and method for treating disease resulting from dioxin toxicity using the compound POSTECH FOUNDATION (KR) 2007-02-08 US disclosed
US-20070032458-A1 Compound having activity for inhibiting dioxin toxicity, pharmaceutical composition comprising the compound and method for treating disease resulting from dioxin toxicity using the compound POSTECH FOUNDATION (KR) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032458-A1 Compound having activity for inhibiting dioxin toxicity, pharmaceutical composition comprising the compound and method for treating disease resulting from dioxin toxicity using the compound CORO1C, DECR1, DECR2 AHR 5/4885GPR174 872/4885APEX1 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.